Background Previous studies have demonstrated that early intervention was the best plan to
inhibit the progression of Alzheimer's disease (AD), which relied on the discovery of early …

Background Measuring synaptic density in vivo with positron emission tomography targeting
synaptic vesicle protein 2A (SV2A) has received much attention recently due to varied …

Histological and biochemical analyses in postmortem tissues have demonstrated
neurodegenerative changes in the cerebral cortex in patients with Alzheimer's disease (AD) …

Sections from the middle frontal gyrus (Brodmann area 46) of autopsy-confirmed Alzheimer's
disease (AD) patients and non-demented subjects were examined for the prevalence of …

Background Synapse loss is an early event that precedes neuronal death and symptom
onset and is considered the best neuropathological correlate of cognitive decline in …

Alzheimer's disease (AD), a serious neurodegenerative disease, is pathologically
characterized by synaptic loss and dysfunction. Synaptic vesicle protein 2A (SV2A) is an …

Background There is accumulating evidence that synaptic loss precedes neuronal loss and
correlates best with impaired memory formation in Alzheimer's disease (AD). Cerebrospinal …

Pro-inflammatory protein S100A9 was established as a biomarker of dementia progression
and compared with others such as Aβ1–42 and tau-proteins. CSF samples from 104 …

Introduction Synapse loss is one of the hallmarks of Alzheimer's disease (AD) and is
associated with cognitive decline. In this study, we tested [18F] SDM-16, a novel …

Background: Several studies have shown increased levels of cerebrospinal fluid (CSF)
synaptosomal-associated protein 25 (SNAP-25) in patients with Alzheimer's disease (AD) …